Just over two years http://fuq.in.net/ www fuq.com
That could bode well for a second Phase III trial of Yervoy, expected to be completed by 2015, which has enrolled patients who are asymptomatic or have only mild symptoms of prostate cancer, and whose cancer has not spread to the lungs or liver. Although previously treated with anti-testosterone drugs, they have not taken chemotherapy.